Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-asparaginase Monotherapy in NK/T Cell Lymphoma
NCT00854425Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jun 2008
- Primary completion
- Jan 2012
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asparaginase escherichia coli in Natural killer T-cell lymphoma (NKTL), sponsored by Fudan University. Primary endpoint: Response Rate at 6 weeks. Started Jun 2008; status: completed.
02
Drugs
asparaginase escherichia coli
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT00854425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854425.